Bone marrow microenvironment and the identification of new targets for myeloma therapy von Podar, K, Chauhan, D, Anderson, K C

Volltext

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications von Podar, Klaus, Anderson, Kenneth C.

Volltext

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment von Fan, F, Bashari, M H, Morelli, E, Tonon, G, Malvestiti, S, Vallet, S, Jarahian, M, Seckinger, A, Hose, D, Bakiri, L, Sun, C, Hu, Y, Ball, C R, Glimm, H, Sattler, M, Goldschmidt, H, Wagner, E F, Tassone, P, Jaeger, D, Podar, K

Volltext

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications von GUPTA, D, TREON, S. P, SCHLOSSMAN, R. L, RICHARDSON, P, RALPH, P, WU, L, PAYVANDI, F, MULLER, G, STIRLING, D. I, ANDERSON, K. C, SHIMA, Y, HIDESHIMA, T, PODAR, K, TAI, Y. T, LIN, B, LENTZSCH, S, DAVIES, F. E, CHAUHAN, D

Volltext

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib von Chauhan, Dharminder, Catley, Laurence, Li, Guilan, Podar, Klaus, Hideshima, Teru, Velankar, Mugdha, Mitsiades, Constantine, Mitsiades, Nicolas, Yasui, Hiroshi, Letai, Anthony, Ovaa, Huib, Berkers, Celia, Nicholson, Benjamin, Chao, Ta-Hsiang, Neuteboom, Saskia T.C., Richardson, Paul, Palladino, Michael A., Anderson, Kenneth C.

Volltext

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 von Hideshima, Teru, Mitsiades, Constantine, Akiyama, Masaharu, Hayashi, Toshiaki, Chauhan, Dharminder, Richardson, Paul, Schlossman, Robert, Podar, Klaus, Munshi, Nikhil C., Mitsiades, Nicholas, Anderson, Kenneth C.

Volltext

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application von Hayashi, Toshiaki, Hideshima, Teru, Akiyama, Masaharu, Podar, Klaus, Yasui, Hiroshi, Raje, Noopur, Kumar, Shaji, Chauhan, Dharminder, Treon, Steven P., Richardson, Paul, Anderson, Kenneth C.

Volltext

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells von Bhanot, H, Reddy, M M, Nonami, A, Weisberg, E L, Bonal, D, Kirschmeier, P T, Salgia, S, Podar, K, Galinsky, I, Chowdary, T K, Neuberg, D, Tonon, G, Stone, R M, Asara, J, Griffin, J D, Sattler, M

Volltext

A novel Bcl-2/Bcl-XL/Bcl-W inhibitor ABT-737 as therapy in multiple myeloma von CHAUHAN, D, VELANKAR, M, ANDERSON, K. C, BRAHMANDAM, M, HIDESHIMA, T, PODAR, K, RICHARDSON, P, SCHLOSSMAN, R, GHOBRIAL, I, RAJE, N, MUNSHI, N

Volltext

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma von Raje, Noopur, Kumar, Shaji, Hideshima, Teru, Ishitsuka, Kenji, Chauhan, Dharminder, Mitsiades, Constantine, Podar, Klaus, Le Gouill, Steven, Richardson, Paul, Munshi, Nikhil C., Stirling, David I., Antin, Joseph H., Anderson, Kenneth C.

Volltext

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis von Podar, K, Gouill, S L, Zhang, J, Opferman, J T, Zorn, E, Tai, Y-T, Hideshima, T, Amiot, M, Chauhan, D, Harousseau, J-L, Anderson, K C

Volltext

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma von Raje, N, Hideshima, T, Mukherjee, S, Raab, M, Vallet, S, Chhetri, S, Cirstea, D, Pozzi, S, Mitsiades, C, Rooney, M, Kiziltepe, T, Podar, K, Okawa, Y, Ikeda, H, Carrasco, R, Richardson, P G, Chauhan, D, Munshi, N C, Sharma, S, Parikh, H, Chabner, B, Scadden, D, Anderson, K C

Volltext

Immunomodulatory analogs of thalidomide inhibit growth of Hs sultan cells and angiogenesis in vivo von LENTZSCH, S, LEBLANC, R, POCLAR, K, DAVIES, F, LIN, B, HIDESHIMA, T, CATLEY, L, STIRLING, D. I, ANDERSON, K. C

Volltext

Novel therapies targeting the myeloma cell and its bone marrow microenvironment von Hideshima, Teru, Chauhan, Dharminder, Podar, Klaus, Schlossman, Robert L, Richardson, Paul, Anderson, Kenneth C

Volltext

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti–multiple myeloma (MM) activity and overcome bortezomib resistance von Chauhan, Dharminder, Li, Guilan, Podar, Klaus, Hideshima, Teru, Shringarpure, Reshma, Catley, Laurence, Mitsiades, Constantine, Munshi, Nikhil, Tai, Yu Tzu, Suh, Nanjoo, Gribble, Gordon W., Honda, Tadashi, Schlossman, Robert, Richardson, Paul, Sporn, Michael B., Anderson, Kenneth C.

Volltext

S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON‐ELIGIBLE PATIENTS WITH NDMM (AGMT‐MM02 TRIAL) von Ludwig, H., Melchardt, T., Sormann, S., Zojer, N., Andel, J., Hartmann, B., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Wöll, E., Schreder, M., Ruckser, R., Bozic, B, Krauth, M.‐T., Petzer, A., Schmitt, C, Machherndl‐Spandl, S., Agis, H., Fillitz, M., Pönisch, W., Knop, S., Paiva, B., Greil, R.

Volltext

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma von Chari, Ajai, Vogl, Dan T, Gavriatopoulou, Maria, Nooka, Ajay K, Yee, Andrew J, Huff, Carol A, Moreau, Philippe, Dingli, David, Cole, Craig, Lonial, Sagar, Dimopoulos, Meletios, Stewart, A. Keith, Richter, Joshua, Vij, Ravi, Tuchman, Sascha, Raab, Marc S, Weisel, Katja C, Delforge, Michel, Cornell, Robert F, Kaminetzky, David, Hoffman, James E, Costa, Luciano J, Parker, Terri L, Levy, Moshe, Schreder, Martin, Meuleman, Nathalie, Frenzel, Laurent, Mohty, Mohamad, Choquet, Sylvain, Schiller, Gary, Comenzo, Raymond L, Engelhardt, Monika, Illmer, Thomas, Vlummens, Philip, Doyen, Chantal, Facon, Thierry, Karlin, Lionel, Perrot, Aurore, Podar, Klaus, Kauffman, Michael G, Shacham, Sharon, Li, Lingling, Tang, Shijie, Picklesimer, Carla, Saint-Martin, Jean-Richard, Crochiere, Marsha, Chang, Hua, Parekh, Samir, Landesman, Yosef, Shah, Jatin, Richardson, Paul G, Jagannath, Sundar

Volltext

Cytokines and signal transduction von Hideshima, Teru, Podar, Klaus, Chauhan, Dharminder, Anderson, Kenneth C.

Volltext

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells von Chauhan, Dharminder, Li, Guilan, Podar, Klaus, Hideshima, Teru, Mitsiades, Constantine, Schlossman, Robert, Munshi, Nikhil, Richardson, Paul, Cotter, Finbarr E., Anderson, Kenneth C.

Volltext

P033 Mcl-1 confers protection of breast cancer cells exposed to hypoxia: therapeutic implications von Bashari, M.H, Fan, F, Arn, M, Vallet, S, Opferman, J, Cardone, M.H, Schneeweiss, A, Jäger, D, Podar, K

Volltext